Versius at United Kingdom

CMR Surgical (founded 2014, Cambridge, UK; private) makes Versius, the genuine challenger among surgical-robot startups and the one that has clearly crossed the regulatory gating event. Versius is a modular multi-arm teleoperated soft-tissue robot that is heavily software-driven, capturing telematic, video, and outcome data. It received US FDA De Novo marketing authorization in October 2024, the first such authorization for a multi-port soft-tissue general-surgery robot, followed by an FDA 510(k) clearance for the next-generation Versius Plus on December 18, 2025 with US commercialization on track for 2026, and a pending gynecology 510(k) submitted on April 29, 2026; it has long been CE-marked and commercial across Europe, Latin America, the Africa-Middle-East region, and Australia, with more than 40,000 procedures completed outside the US by company reporting.

The registry records it at commercial maturity with an active lifecycle. An important current-state correction: the 2021 roughly $3 billion SoftBank-led valuation story is frozen in time, the company went through real restructuring in 2023 with about 350 redundancies, and it was recapitalized with more than $200 million in April 2025, while reported figures of a roughly $3.1 billion 2025 valuation and a potential $4 billion sale are rumor-tier aggregator claims that are not registered.

On AI substance the shipped reality is a data-capture and analytics ecosystem with the surgeon in full control; the physical-AI framing is forward-looking, anchored in a March 2026 NVIDIA IGX Thor partnership to evaluate AI for a future Versius, with no autonomous or AI-assisted intraoperative feature cleared or shipped.